ANTICOAGULATION STRATEGIES

New study compares cost-effectiveness of blood clot treatments in cancer patients

A new study to be published in the Annals of Internal Medicine examines the cost-effectiveness of the four most utilized anticoagulation strategies for blood clots, which include LMWH, apixaban, edoxaban and rivaroxaban. Authors of the study include oncologist and Assistant Professor of Medicine Shuchi Gulati, a clinician scientist with UC Davis, and Professor Emeritus of Clinical Medicine Mark H. Eckman with the University of Cincinnati.